IL2 and type 1 diabetes mellitus: Phase 1, single-arm, open-label (NCT02772679) trial evaluating safety and preliminary efficacy of polyclonal regulatory T cells (Tregs) plus IL-2 in patients with T1D. Primary outcome measures include safety, changes in beta cell function (C-peptide in response to serial MMTT), glycemia (HbA1c), and Treg survival (69).